Trethera and UCLA Publish Comprehensive Review Highlighting Deoxycytidine Kinase as a Novel Metabolic Target for Cancer Therapy

TRE-515Positive

AI Analysis

Summary

Trethera and UCLA published a peer-reviewed manuscript highlighting deoxycytidine kinase (dCK) as a novel metabolic target for cancer therapy, with TRE-515 identified as the first clinically tested dCK inhibitor.

Importance:3/10

Sentiment:

0.40

publicationpeer-reviewedresearchcancermetabolic_target

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on July 16, 2026 2:44 PM

Read Original